Lundbeck receives European marketing approval for schizophrenia drug  

Pharmaceutical company Lundbeck has received approval from the CHMP to market schizophrenia drug Serdolect in Europe

Pharmaceutical company Lundbeck has received approval from the CHMP [Committee for Medicinal Products for Human Use – Ed] to market schizophrenia drug Serdolect in Europe. Marketing authorisation for Serdolect was temporary suspended by CHMP in 1998. Since then, Lundbeck has conducted extensive studies involving 5,000 patients, which have confirmed that Serdolect can be safely prescribed. Serdolect is expected to be relaunched in Europe in H2 2005.

Anders Gersel Pedersen, development director at Lundbeck says: It is very pleasing that we have received the approval. It is something we have fought for over a long time". Henrik D. Simonsen, equity analyst at Enskilda Securities says that it is quite an important piece of news: "I estimate that total sales in Europe could be around a couple of hundred million DKK. In addition there is the American market, if and when Lundbeck gains approval to sell there", he adds. The news is reported by national daily newspaper Jyllands-Posten and on Lundbeck's website.

Lundbeck is headquartered in Copenhagen, and develops and produces drugs for the treatment of psychiatric and neurological disorders. In 2004, the company generated revenues of DKK 9.7 bn (USD 1.6 bn). The number of staff is approximately 5,000.

Link > Lundbeck 

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×